ArticleBMC nephrology2025
Outcomes of community-acquired acute kidney injury: a prospective comparative cohort study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prospective studies on the clinical course and outcome of community-acquired acute kidney injury (CA-AKI) are lacking. We hypothesized that similar to patients with hospital-acquired AKI, CA-AKI patients experience adverse outcomes when compared with a control group of non-AKI patients. This was a prospective comparative cohort study in which serum creatinine (SCr) of all individuals visiting a university hospital's emergency (ED) over an 11-month period were examined for the presence of AKI. A total of 512 AKI cases (48% women) were identified, and 1024 control cases matched on age, sex and time of ED visit (1:2) were randomly selected. Following the visit, the participants were monitored through electronic medical records for up to 15 months, and hospital outcomes, serum SCr measurements and mortality were evaluated. The mean (±SD) age of AKI cases and controls was 67.1 ± 16.6 years and 67.2 ± 16.2 years, respectively. Compared with the control group, AKI cases were more likely to require hospitalization (77.1% vs. 59.9%, p < 0.001), had longer hospital stay (4 days [IQR 1-10] vs. 2 days [IQR 0-5], p < 0.001), higher 90-day mortality (AKI stage 1: HR 2.35, 95% CI, 1.23-4.50; AKI stages 2 and 3: HR 4.19, 95% CI, 2.22-7.92) and one-year mortality (AKI stage 1: HR 1.54, 95%CI, 1.00-2.37; AKI stages 2 and 3: HR 2.42, 95%CI, 1.50-3.90) and were more likely to develop new AKI (HR 1.60, 95%CI 1.15-2.23), incident CKD stage 3 and higher (39 (10.5%) vs 57 (7%), p = 0.037) and a major adverse kidney event (101 (19.6%) vs 119 (11.6%), p < 0.001) in the year following ED visit. Patients with CA-AKI visiting the ED have significantly worse outcomes than controls, including higher mortality, more frequent new AKI and progression to CKD stages 3 and higher. This calls for careful follow-up of these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.